Kangstem Biotech

KOR | ENG

주메뉴

Company
- Company
  
  Kangstem Biotech is
  engaged in various fields
  of bio-innovation.
- About Us
- Kangstem Biotech
- Global R&D Center
- Stem Cell GMP Center
- Welcome Message
- Vision & Mission
- History
- Location
Business
- Business
  
  Kangstem Biotech is
  engaged in various fields
  of bio-innovation.
- Stem Cell Therapy
- FURESTEM-OA Kit Inj.
- FURESTEM-AD® Inj.
- FURESTEM-RA® Inj.
- Advanced Regenerative Medicine
- Organoid
- Organoid
- Skin Organoid
- Islet Organoid
- CDMO Business
- CDMO
- JUVENTAS
- Stem Cell Culture Business
- Health&Beauty Business
R & D
- R & D
  
  Kangstem Biotech is
  engaged in various fields
  of bio-innovation.
- Core Technology
- Umbilical Cord Blood Stem Cell
- High-Compact Technology Strategy
- R&D Achievements
Investors
- Investors
  
  Kangstem Biotech is
  engaged in various fields
  of bio-innovation.
- Notice
- PR
- Press Release
- PR Resource Center

Core Technology

R&D Achievements

Kangstem Biotech is advancing innovative therapies through its cell therapy and organoid platforms, with a strong foundation in scientific evidence and clinical potential.

R&D Achievements

2020.06

Therapeutic Effects of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells Combined with Cartilage Acellular Matrix Mediated Via Bone Morphogenic Protein 6 in a Rabbit Model of Articular Cruciate Ligament Transection

Journal : Stem Cell Reviews and Reports

2020.04

TGF-β secreted by human umbilical cord blood-derived mesenchymal stem cells ameliorates atopic dermatitis by inhibiting secretion of TNF-α and IgE

Journal : STEM CELLS

2019.10

Preconditioning with interleukin-1 beta and interferon-gamma enhances the efficacy of human umbilical cord blood-derived mesenchymal stem cells-based therapy via enhancing prostaglandin E2 secretion and indoleamine 2,3-dioxygenase activity in dextran sulf

Journal : Journal of Tissue Engineering and Regenerative Medicine

2019.06

Therapeutic effect of long-interval repeated intravenous administration of human umbilical cord blood-derived mesenchymal stem cells in DBA/1 mice with collagen-induced arthritis

Journal : Journal of Tissue Engineering and Regenerative Medicine

2019.05

Interferon-γ-mediated secretion of tryptophanyl-tRNA synthetases has a role in protection of human umbilical cord blood-derived mesenchymal stem cells against experimental colitis

Journal : BMB Reports

2019.04

Human umbilical cord blood plasma alleviates age-related olfactory dysfunction by attenuating peripheral TNF-α expression

Journal : BMB Reports

2019.03

Generation of Genetically Stable Human Direct-Conversion-Derived Neural Stem Cells Using Quantity Control of Proto-oncogene Expression.

Journal : Molecular Therapy - Nucleic Acids

2019.02

Far-Infrared Irradiation Inhibits Adipogenic Differentiation and Stimulates Osteogenic Differentiation of Human Tonsil-Derived Mesenchymal Stem Cells: Role of Protein Phosphatase 2B

Journal : CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

2018.12

Generation of Human Neural Stem Cells by Direct Phenotypic Conversion.

Journal : Results and Problems in Cell Differentiation

2018.10

Conditioned media from human umbilical cord blood-derived mesenchymal stem cells stimulate rejuvenation function in human skin.

Journal : Biochemistry and Biophysics Reports

1 2 3 4

Company

About Us

Business

Stem Cell Therapy

Organoid

CDMO Business

Health&Beauty Business

R&D

Core Technology

Investors

Notice